Cao Juan, Liu Guang-Shu, Zou Ning-Zhen, Zhang Huang, He Xiao-Xiao, Sun Ping-Li, An Hong-Jian, Shen Hong
Department of Pathology, Southern Medical University, Guangzhou, Guangdong, China.
Department of Pathology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
Neoplasma. 2022 Feb 10. doi: 10.4149/neo_2022_210922N1340.
miR-200c-3p is aberrantly expressed in numerous cancers, but its underlying mechanisms in nephroblastoma are unknown. In our study, the differentially regulated miRNAs between the nephroblastoma tissues and adjacent non-neoplastic renal tissues were screened based on microarray analysis. The miR-200c-3p expression in nephroblastoma tissues and cells was detected by qRT-PCR. Then, the effects of miR-200c-3p mimic or inhibitor on cell proliferation, invasion, and migration were evaluated by CCK-8 assay, plate colony formation assay, soft agar assay, Transwell, and wound-healing assay in SK-NEP-1 and G401 cells. Afterward, the target gene of miR-200c-3p was predicted by TarBase, miRTarBase, miRDB softwares, and then verified by dual-luciferase reporter gene assay. The in vivo effects of miR-200c-3p on pathological changes and tumor volume were investigated in tumor xenograft mice by H&E staining and in vivo fluorescence imaging. ChIP assay was used to evaluate the relationship between histone acetyltransferase E1A-binding protein p300 (EP300) and P27, and the relationship of the role of miR-200c-3p in nephroblastoma and the AKT/FOXO1/p27 signaling pathways was evaluated by western blotting. Our study shows that miR-200c-3p was downregulated in nephroblastoma tissues and cells, and EP300 was a target gene of miR-200c-3p. Furthermore, miR-200c-3p mimic decreased cell proliferation and inhibited cell migration and invasion in nephroblastoma. Mechanistically, miR-200c-3p could inhibit p-AKT activity and enhance p-FOXO1 and p27 expression. Notably, the transcription factor P27 could bind to the EP300 promoter. This study demonstrates a new approach to treat nephroblastoma.
miR-200c-3p在多种癌症中表达异常,但其在肾母细胞瘤中的潜在机制尚不清楚。在我们的研究中,基于微阵列分析筛选了肾母细胞瘤组织与相邻非肿瘤性肾组织之间差异调节的微小RNA。通过qRT-PCR检测肾母细胞瘤组织和细胞中miR-200c-3p的表达。然后,通过CCK-8法、平板集落形成试验、软琼脂试验、Transwell试验和划痕愈合试验,评估miR-200c-3p模拟物或抑制剂对SK-NEP-1和G401细胞增殖、侵袭和迁移的影响。随后,通过TarBase、miRTarBase、miRDB软件预测miR-200c-3p的靶基因,然后通过双荧光素酶报告基因试验进行验证。通过苏木精-伊红染色和体内荧光成像,在肿瘤异种移植小鼠中研究了miR-200c-3p对病理变化和肿瘤体积的体内影响。采用染色质免疫沉淀试验评估组蛋白乙酰转移酶E1A结合蛋白p300(EP300)与P27之间的关系,并通过蛋白质免疫印迹法评估miR-200c-3p在肾母细胞瘤中的作用与AKT/FOXO1/p27信号通路之间的关系。我们的研究表明,miR-200c-3p在肾母细胞瘤组织和细胞中表达下调,EP300是miR-200c-3p靶基因。此外,miR-200c-3p模拟物可降低肾母细胞瘤细胞增殖并抑制细胞迁移和侵袭。机制上,miR-200c-3p可抑制p-AKT活性并增强p-FOXO1和p27表达。值得注意的是,转录因子P27可与EP300启动子结合。本研究证明了一种治疗肾母细胞瘤的新方法。